Gunnar Gottschalk Ph.D., CEO and Section Chief, Translational Science | Professor (adj.) UW-Milwaukee Department of Chemistry and Biochemistry

Dr. Gottschalk has been with Simmaron Research since its formation. Prior to attending graduate school, Dr. Gottschalk was the lead research coordinator for Sierra Internal Medicine and was responsible for the execution of several large multi-centered investigations in ME/CFS funded by NIH, The Chronic Fatigue Initiative, The Open Medicine Institute, and the Centers for Disease Control. In 2020, he was named the Foundation’s CEO. Throughout the COVID-19 pandemic, Dr. Gottschalk led Simmaron’s Local Response to COVID-19 Program that provided free critical early access to COVID testing for residents of North Lake Tahoe, supported the development of the Simmaron COVID-19 Biobank and initiated a number of related research projects. In 2021, Dr. Gottschalk recruited Avik Roy, PhD, to be Simmaron’s Chief Scientific Officer. Since then, the two have received multiple competitive grants, including a Ramsay Award from SolveME and an NIH R21. At present, Dr. Gottschalk is the PI for Simmaron’s multi-centered clinical trial of Rapamycin in ME/CFS. His laboratory is located at the Indiana Center for Biomedical Innovation (ICBI) on the campus of the Indiana University Methodist Hospital in Indianapolis, IN. Dr. Gottschalk is an Adjunct Professor in the Department of Chemistry and Biochemistry at the University of Wisconsin Milwaukee and a member of the Milwaukee Institute of Drug Discovery (MIDD).

https://www.ncbi.nlm.nih.gov/myncbi/1HMrmLhAo2aAln/bibliography/public/